Solutions

Organoid Service

Organoid
Disease Modeling
Oncology

º Organoid

Adult tissue & PSC-derived organoid based drug evaluation service

Organoids are three-dimensional mini-organs artificially created in vitro replicating the cellular composition, structure, and functional specificity of the organ.
A high-tech and high-quality human iPSC-derived 3D organoid modeling service is provided, seamlessly integrating non-animal resources.

Lambda Biologics, Pioneering Excellence in Organoid Technology

Lambda Biologics specializes in cutting-edge organoid-based solutions, offering unparalleled services for the pharmaceutical and biotechnology industries.
Comprehensive support is provided for pre-clinical research and drug development, ensuring innovative and reliable results.
By leveraging advanced mimicking capabilities and diverse tissue sources, Disease Medeling provide researchers with deeper insights into drug efficacy and safety.
These solutions streamline the path from discovery to development, enhancing predictability and clinical success rates.

Normal Organoid

Gastric

3500€+

Normal Organoid

Liver Organoid

3500€+

Normal Organoid

Midbrain Organoid

9275€+

Normal Organoid

Cerebral Organoid

2388€+

Normal Organoid

Lung Organoid

4929€+

Normal Organoid

Retinal Organoid

4350€+

Normal Organoid

Adenoid Organoid

1435€+

Normal Organoid

Tonsil Organoid

1435€+

Normal Organoid

Lacrimal Gland Organoid

4850€+

Normal Organoid

Salivary Gland Organoid

2850€+

Normal Organoid

Cardiac Organoid

5500€+

Normal Organoid

Kidney Organoid

2830€+

Normal Organoid

Skin & Hair Folicle Organoid

3189€+

Normal Organoid

Intestinal Organoid

880€+

Organoid type of Lambda Biologics

Established Cancer Organoid

Adult tissue derived organoid

Organoids derived from adult stem cells isolated from specific tissues, such as the intestine, liver, lungs, salivary glands, and tonsils, can be used for drug evaluation and other research applications.

iPSC-derived organoid

Organoids generated from induced pluripotent stem cells (iPSCs) undergo differentiation and maturation processes to mimic specific organs, enabling the creation of models such as the brain, cardiac, kidney, skin, and retina.

Broad application of the Disease Medeling

Drug Screening: Efficiently evaluate the efficacy of compounds using organoid platforms.
Drug Toxicity Testing: Ensure safety with physiologically relevant toxicity assessments.
Disease Modeling: Replicate human disease conditions for precise pre-clinical studies.

Probiotics effect in Leaky Gut model

The restorative effect of probiotics co-culture on tight junctions in the LPS-induced Leaky gut organoid model.

Antiviral drug effect in SARS-CoV-2 infected Tonsil organoid

Accumulation of SARS-CoV-2 particles on the apical surface of tonsil organoids on day 3.

Inhibition of (Left) viral RNA titers and (Right) viral nucleocapsid gene expression on day 2 after treatment of SARS-CoV-2–infected organoids with increasing concentrations of remdesivir.

º Oncology

Patient cancer organoid based drug evaluation service

The oncology drug efficacy evaluation platform is based on patient-derived organoids (PDOs).
This advanced platform enables the evaluation of oncology agents and immunotherapeutics by utilizing a co-culture system incorporating immune cells from the tumor microenvironment.

Next-Generation Anti-Cancer Drug Development & Efficacy Evaluation with Patient-Derived Organoids (PDOs)

High-Fidelity Preclinical Models

Oncology utilizes 3D patient-derived organoids (PDOs) cultured directly from tumor biopsies.
These models preserve the original tumor’s genetic and phenotypic characteristics, providing a more clinically relevant system than traditional 2D cell lines or animal models.

High-Fidelity Preclinical Models

A comprehensive biobank of PDOs, derived from a wide range of cancer types, forms an expansive repository that supports robust screening efforts.
This resource enables the identification of drug candidates across diverse tumor profiles and informs strategic decision-making throughout the R&D pipeline.